Regeneron Pharmaceuticals, Inc. Share Price
Equities
REGN
US75886F1075
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
980.2 USD | +1.06% | -0.49% | +11.60% |
Sales 2024 * | 1.38TCr 1,15300Cr | Sales 2025 * | 1.49TCr 1,24500Cr | Capitalization | 11TCr 8,82000Cr |
---|---|---|---|---|---|
Net income 2024 * | 396Cr 33TCr | Net income 2025 * | 441.9Cr 37TCr | EV / Sales 2024 * | 6.99 x |
Net cash position 2024 * | 908.31Cr 76TCr | Net cash position 2025 * | 1.49TCr 1,24000Cr | EV / Sales 2025 * | 6.09 x |
P/E ratio 2024 * |
29
x | P/E ratio 2025 * |
25.9
x | Employees | 13,677 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.42% |
Latest transcript on Regeneron Pharmaceuticals, Inc.
1 day | +1.06% | ||
1 week | -0.49% | ||
1 month | +8.49% | ||
3 months | -0.27% | ||
6 months | +20.29% | ||
Current year | +11.60% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 08/88/08 | |
Chief Executive Officer | 71 | 08/88/08 | |
Director of Finance/CFO | 53 | 01/03/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 12/10/12 |
Chief Executive Officer | 71 | 08/88/08 | |
Michael Brown
BRD | Director/Board Member | 83 | 01/91/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.27% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 980.2 | +1.06% | 833,169 |
30/24/30 | 969.9 | +0.35% | 444,018 |
29/24/29 | 966.5 | -0.69% | 346,743 |
28/24/28 | 973.2 | -1.20% | 336,857 |
24/24/24 | 985 | +0.45% | 259,279 |
Delayed Quote Nasdaq, May 01, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr | |
+7.26% | 774.73Cr |
- Stock Market
- Equities
- REGN Stock